Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
Pennington Biomedical Research Center · Medpace (United States) · +7 more institutions
Abstract
No abstract available for this paper.
Citation impact
- FWCI
- 44.08
- Percentile
- 100%
- References
- 35
Authors
9- WTW. Timothy GarveyCorresponding
Pennington Biomedical Research Center, Medpace (United States), Duke University, University of Alabama at Birmingham, Birmingham VA Medical Center
- DHDonna H. Ryan
Pennington Biomedical Research Center, Medpace (United States), Duke University, University of Alabama at Birmingham, Birmingham VA Medical Center
- MLMichelle Look
Pennington Biomedical Research Center, Medpace (United States), Duke University, University of Alabama at Birmingham, Birmingham VA Medical Center
- KMKishore M. Gadde
Pennington Biomedical Research Center, Medpace (United States), Duke University, University of Alabama at Birmingham, Birmingham VA Medical Center
- DBDavid B. Allison
Pennington Biomedical Research Center, Medpace (United States), Duke University, University of Alabama at Birmingham, Birmingham VA Medical Center
Topics & keywords
- Phentermine
- Topiramate
- Placebo
- Overweight
- Weight loss
- Medicine
- Obesity
- Diabetes mellitus
- Good health and well-being